In many cancers, PIP3 signaling is enhanced due to mutations in components of the signaling pathway, including EGF receptors, PI3-kinases, PTEN, Ras GTPases, and a major effector of PIP3, AKT6, 7, 8, 9, 10, 11, 12, 13. This evidence concerns the gene PTEN and cancer.